The treatment of woodchuck hepatitis virus infections with 1-(2'-deoxy-2'-fluoro-4-D-arabinofuranosyl)-5-iodocytosine (FIAC) and 1-(2'-deoxy-2'-fluoro-4-D-arabinofuranosyl)-5-methyluracil (FMAU), given intraperitoneally, caused complete and permanent decrease of serum virus endogenous DNA polymerase and viral DNA in all treated woodchucks but was associated with severe toxicity. By contrast 1-(2'-deoxy-2'-fluoro-l-D-arabinofuranosyl)-5-ethyluracil (FEAU) induced a sustained, although less dramatic, decrease of viral replication without apparent toxic effect. FEAU was also effective when given orally. However, in both cases this inhibitory effect was transient. (7) is often associated with chronic hepatitis leading to liver cirrhosis and hepatocellular carcinoma. So far none of the current treatments, including vidarabine (11, 15), acyclovir (16), alpha interferon (3), and immunomodulatory compounds (18), have been able to satisfy the clinical needs. The discovery of HBV-related animal viruses designated hepadnavirus (8) in woodchucks, ground squirrels, and Pekin ducks offers new possibilities to test potential anti-HBV agents (10, (12) (13) (14) . Among the three animal hepadnaviruses, the woodchuck hepatitis virus (WHV) is the most closely related to HBV (6). The natural courses of WHV and HBV chronic hepatitis are comparable, especially progression to hepatocellular carcinoma (5). Thus we investigated in vivo in the woodchuck model the antiviral activity of three compounds of the family of 2'-fluoro-substituted arabinosyl pyrimidine analogs (4)
The treatment of woodchuck hepatitis virus infections with 1-(2'-deoxy-2'-fluoro-4-D-arabinofuranosyl)-5-iodocytosine (FIAC) and 1-(2'-deoxy-2'-fluoro-4-D-arabinofuranosyl)-5-methyluracil (FMAU), given intraperitoneally, caused complete and permanent decrease of serum virus endogenous DNA polymerase and viral DNA in all treated woodchucks but was associated with severe toxicity. By contrast 1-(2'-deoxy-2'-fluoro-l-D-arabinofuranosyl)-5-ethyluracil (FEAU) induced a sustained, although less dramatic, decrease of viral replication without apparent toxic effect. FEAU was also effective when given orally. However, in both cases this inhibitory effect was transient. (7) is often associated with chronic hepatitis leading to liver cirrhosis and hepatocellular carcinoma. So far none of the current treatments, including vidarabine (11, 15) , acyclovir (16) , alpha interferon (3), and immunomodulatory compounds (18) , have been able to satisfy the clinical needs. The discovery of HBV-related animal viruses designated hepadnavirus (8) in woodchucks, ground squirrels, and Pekin ducks offers new possibilities to test potential anti-HBV agents (10, (12) (13) (14) . Among the three animal hepadnaviruses, the woodchuck hepatitis virus (WHV) is the most closely related to HBV (6) . The natural courses of WHV and HBV chronic hepatitis are comparable, especially progression to hepatocellular carcinoma (5). Thus we investigated in vivo in the woodchuck model the antiviral activity of three compounds of the family of 2'-fluoro-substituted arabinosyl pyrimidine analogs (4): 1-(2'-deoxy-2'-fluoro-,3-D-arabinofuranosyl)-5-iodocytosine (FIAC), 1-(2'-deoxy-2'-fluoro-,-D-arabinofuranosyl)-5-methyluracil (FMAU), and 1-(2'-deoxy-2'-fluoro-i-D-arabinofuranosyl)-5-ethyluracil (FEAU). Indeed, the triphosphate derivatives of these compounds, known as antiherpetic agents, specifically inhibit the viral DNA polymerases of HBV and WHV in vitro (9) . FIAC, FMAU, and FEAU were synthesized in the laboratory of organic chemistry of the Memorial Sloan-Kettering Cancer Center. Adenine arabinoside monophosphate (araAMP) was supplied by the Warner Lambert Co. Woodchucks chronically infected with WHV were obtained from our breeding colony initially established from animals imported from Pennsylvania. WHV replication was followed by the detection of WHV DNA polymerase activity in serum by using virus pelleted by ultracentrifugation through a sucrose cushion and by the detection of WHV DNA in serum by the hybridization spot test of Cova et al. (2) . The relative amount of WHV DNA in serum was estimated as previously described (2) . Forty-six WHV chronic carrier woodchucks were involved in two independent experiments. These animals were divided into two groups: one group of high replicators with WHV endogenous DNA polymerase * Corresponding author. activity higher than 1,000 cpm and the other group including moderate and low replicators (500 to 1,000 and <500 cpm, respectively). Generally, high replicators were younger (age range, 1 to 2 years); conversely, moderate and especially low replicators were older (3 to 4 years of age). In many cases, we observed that lower levels of WHV replication were associated with the development of hepatocellular carcinoma, which is often correlated with an increasing level of alphafeto protein (1) . As in other centers (17) , 50% of our WHV chronic carrier animals develop hepatocellular carcinoma after 2 years of age, and 100% develop it within 4 years. All two treatment protocols included woodchucks with high and low levels of WHV replication.
Hepatitis B virus (HBV) infection
In the first experiment (Table 1) , all compounds were given intraperitoneally. FIAC at 20 mg/kg per day (Fig. 1C ) and FMAU at 2, 0.8, and even 0.2 mg/kg per day (Fig. 1B) induced a complete and long-lasting decrease of WHV replication, reflected by the absence of WHV DNA and DNA polymerase activity in serum. However, this antiviral effect was associated with severe toxicity: all treated animals showed a marked anorexia during treatment and died within 6 months. The early death was associated with central nervous system toxicity, and the later death was associated with renal insufficiency. FEAU induced a decrease of WHV replication that started at a dose of 0.04 mg/kg per day and became progressively more pronounced for doses of 0.2 and 2 mg/kg per day. The inhibitory effect was immediate and long lasting but not permanent (Fig. 1D) . All animals survived this treatment protocol. Three treated low-replicator animals with tumors died 3, 5, and 8 weeks after the end of the treatment, as did two control animals. A significant decrease of viral replication was also observed during araAMP treatment, used for comparison (Fig. 1E) . However, viral replication resumed immediately after discontinuation of araAMP in all animals.
In the following experiment (Table 2) , FEAU was given orally at 0.04 mg/kg per day to five low replicators and at 0.2 mg/kg per day to five high replicators for 22 days (Fig. 2) . This therapy was associated with a decrease of viral replication in all treated animals. The dose was then increased for a second phase of 37 days, whenever replication persisted. The viral replication was reduced to low levels in all animals. These results were confirmed by the Southern blot analysis of intracellular WHV DNA in liver biopsies as described previously (10 (4) . This prompted the search for other compounds from the same family with lower toxicity. As previously demonstrated in experiments against herpesvirus (4), FEAU was less active than FMAU but more active than araAMP against WHV and appeared well tolerated when given intraperitoneally. Interestingly, FEAU was also effective given orally, although to a lesser degree. The inhibition of viral replication although sustained was not permanent. This could be explained by the persistence of some WHV DNA replicative forms, especially the covalently closed circular DNA, in the livers of treated animals. We believe that some of the side effects observed with oral FEAU in this study could be linked to some of the experimental conditions (drug gavage and state of partial hibernation of treated woodchucks). Thus, FEAU appears as the most promising anti-HBV candidate described so far and warrants further studies. LITERATURE CITED
